Paris, San Francisco, and Oxford (United Kingdom)- August 25, 2025 – Lauxera Capital Partners (“Lauxera”) today announced that Terumo Corporation (TSE: 4543, “Terumo”) has entered into a definitive agreement dated August 23, 2025, with Organox Limited (“Organox” or the “Company”) and its shareholders to acquire all outstanding shares of Organox. Upon completion of the transaction, Organox will become a wholly owned subsidiary of Terumo. The total transaction value is approximately USD $1.5 billion*.
Founded in 2008 as a spin-off from the University of Oxford, Organox is a pioneering medtech company specialized in advanced organ preservation devices for organ transplantation. The company’s products preserve organs for long periods by circulating oxygen and nutrient-rich perfusate through the organ at near-body temperature.
Lauxera made its initial Organox investment in July, 2023, leading an over-subscribed round. Lauxera’s Co-Founding Partner, Samuel Levy, joined the Organox board and served on its Audit, Remuneration and Transaction committees. Samuel also represented Organox on the board of eGenesis inc. following Organox’s strategic investment in eGenesis’s $191m Series D financing.
“It has been an honor supporting Organox’s outstanding growth through sweat, coaching, and unwavering belief in the transformative potential of the company,” said Samuel Levy, MD. “The tireless effort and commitment of Organox’s management and team members have enabled more than six thousand patients around the world to receive donated livers, the ultimate gift of life.”
“I feel blessed to have had the opportunity to work with the Lauxera team,” said Craig Marshall, CEO of Organox. “Week after week, Sam pushed me and my team to think ‘AND’ instead of ‘OR’, go faster, minimize risk, and maximize opportunities. With Lauxera’s help, we scaled from a few, initial customer success stories in the US to a nationwide presence.”
“Sam and Lauxera have significant experience supporting medtech companies growing revenue more than 100% year-over-year,” added Oern Stuge, Executive Chairman of Organox. “That kind of growth puts strain on the entire organization. Lauxera helped us bring in the commercial, regulatory, manufacturing, quality, and strategic finance talent we needed to deliver, along with the right mindset to succeed in the US.”
This acquisition marks Terumo’s strategic entry into the organ transplantation-related sector—a field with significant unmet medical need and strong growth potential. Under Terumo’s ownership, Organox will continue scaling within and outside the United States further supporting surgeons performing these life-saving procedures.
Once completed, this transaction will represent Lauxera’s first exit as an emerging Healthtech specialist private equity manager.
“We are extremely proud of this very successful outcome for our Fund I, its investors and co-investors,” said Pierre Moustial, Co-Founding Partner of Lauxera. “Organox is a textbook case articulating our firm’s core investment thesis. We scale up European Healthtech companies via commercial execution in global markets, with a strong focus on the US.”
“Since our initial investment roughly two years ago, Organox has multiplied its revenue more than five-fold,” said Samuel Levy. “We feel privileged to have had the opportunity to intensely support this successful US commercialization scale-up.”
*This figure is a preliminary estimate as of the date of this press release. The final transaction value will be determined upon completion of the acquisition, following adjustments for Organox’s cash and cash equivalents, interest-bearing debt, and working capital.
About OrganOx
OrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 6,000 liver transplants to date to keep donor livers in a metabolically active state outside the body so that functional assessment of the organ can be performed prior to transplant, leading to an increased number of organs available for transplant.
Learn more at www.organox.com
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthtech” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting Healthtech ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large
”Although more than 9,000 liver transplants are performed each year in the United States, more than 1,500 people die each year waiting for a liver on the transplant list. This represents only ~3% of the 50,000 Americans who die each year from liver failure. This is unacceptable. Lauxera is proud and honored to back the OrganOx team and its global commercial scale up.
Samuel LevyFounding Partner at Lauxera
